Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Carcinoma, Hepatocellular 29Carcinoma, Renal Cell 17Liver Neoplasms 12Breast Neoplasms 10Carcinoma, Non-Small-Cell Lung 9Neoplasms 5Leukemia, Myeloid, Acute 5Kidney Neoplasms 5Neoplasm Metastasis 4Urinary Bladder Neoplasms 3Thyroid Neoplasms 3Prostatic Neoplasms 3Lung Neoplasms 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Lymphocytic, Chronic, B-Cell 3Colorectal Neoplasms 3Carcinoma 3Thyroid Carcinoma, Anaplastic 2Thyroid Cancer, Papillary 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Myelodysplastic Syndromes 2Multiple Myeloma 2Breast Neoplasms, Male 2Blast Crisis 2Adenocarcinoma, Follicular 2Urethral Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Triple Negative Breast Neoplasms 1Thyroid cancer, medullary 1

Interventions

vandetanib 1lenvatinib 1cabozantinib 1Sorafenib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Thyroid cancer, medullary × Sorafenib × Clear all
NCT03630120 2021-07-14

Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
6 enrolled 9 charts
EndocrineHead & Neck

Thyroid cancer, medullary, Thyroid Cancer, Papillary, Thyroid Diseases, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡